Squamous Cell Carcinoma (Skin)NCT07809191
Hair Regrowth Following Partial Thickness Removal of SSCIS
A study testing Partial Thickness Excision in people with Squamous Cell Carcinoma (Skin) and Squamous Cell Carcinoma in Situ, run by Cooper Norcross Health.
Trial summary
Participants are being approached to participate in this study because they are undergoing surgery for a skin cancer known as squamous cell carcinoma in situ (SCCIS) on the scalp. Standard surgical techniques may remove deeper structures that contain hair follicles, which can result in permanent hair loss. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Squamous Cell Carcinoma (Skin), Squamous Cell Carcinoma in Situ, Alopecia
- What is being tested?
- Partial Thickness Excision
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2026to 17 Jul 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults ≥ 18 years old
- Histologically confirmed SCCIS
- Lesions located in the hair-bearing scalp
- Ability to provide informed consent
Who cannot join
- Invasive, poorly differentiated, or high-risk SCC features (e.g., perineural invasion)
- Recurrent SCC at the same site
- Prior radiation therapy to the scalp
- Scarring alopecia or active inflammatory scalp disease at the treatment site
- Immunosuppression that, in the investigator's judgement, increases oncologic risk
- Use of topical minoxidil, oral minoxidil, finasteride, spironolactone, or other hair-growth promoting agents
About this study
Official title: Hair Regrowth Following Partial Thickness Stages in Mohs Micrographic Surgery of Squamous Cell Carcinoma in Situ: A Prospective Pilot Study
Participants are being approached to participate in this study because they are undergoing surgery for a skin cancer known as squamous cell carcinoma in situ (SCCIS) on the scalp. Standard surgical techniques may remove deeper structures that contain hair follicles, which can result in permanent hair loss. This study evaluates whether a modified surgical technique, known as partial thickness excision, can preserve hair growth and improve cosmetic outcomes. Participation involves minimal risk beyond the standard risks of Mohs surgery. If patients choose to participate, their surgery will be performed using this technique, and photographs will be taken over time to evaluate hair regrowth and healing.
- Being tested
- Partial Thickness Excision
- Keywords
- mohs micrographic surgery, partial thickness excision
- Medical subject headings
- Carcinoma, Squamous Cell, Squamous Intraepithelial Lesions, Alopecia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Partial Thickness ExcisionProcedure or surgery
Participants will receive excision of their squamous cell carcinoma in situ of the scalp via partial thickness excision (removal of epidermal and superficial dermal tissue) in an effort to preserve hair follicles and hair growth potential.
| Study group | Role | What they receive |
|---|---|---|
| Partial Thickness Excision | Experimental | Participants will receive excision of their squamous cell carcinoma in situ of the scalp via partial thickness excision (removal of epidermal and superficial dermal tissue) in an effort to preserve hair follicles and hair growth potential. Receives: Procedure: Partial Thickness Excision |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hair Growth measured clinically by hair density percentage compared to baseline photo
To evaluate hair growth following partial thickness excision of SCCIS at 3 and 6 months post-procedure.
Measured: 3 and 6 months post-procedure.
Secondary outcomes (3)
Clearance of SCCIS measured by Mohs surgeons' interpretation of margins on surgical slides.
To assess clinical and histologic clearance of SCCIS treated with partial-thickness excision.
Measured: Immediately following the final Mohs stage during the index procedure
Patient Satisfaction measured via patient satisfaction questionnaire
To evaluate patient-reported satisfaction with hair density and cosmetic outcome.
"Are you satisfied with amount of hair//appearance of skin/result of treatment?" etc. on scale of 1-10. 1 being not satisfied and 10 being very satisfied/.
Measured: 3 and 6 months post-procedure
Complications
To document wound-healing, complications, and the need for additional treatment.
Measured: 2 weeks post-procedure, 3 months post-procedure, and 6 months post-procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2026
- Study start1 Sep 2026 (estimated)
- Primary completion17 Jul 2027 (estimated)
- Study completion17 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Squamous Cell Carcinoma (Skin)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cooper Norcross Health
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Naomi Lawrence, Cooper Norcross Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07809191
- Sponsor's protocol ID
- 26-044
- Status last verified
- Jul 2026
- First submitted
- 4 Aug 2026
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hair Regrowth Following Partial Thickness Stages in Mohs Micrographic Surgery of Squamous Cell Carcinoma in Situ: A Prospective Pilot Study
- ClinicalTrials.gov ID
- NCT07809191
- Acronym / sponsor ID
- 26-044
- Keywords
- mohs micrographic surgery, partial thickness excision
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Cooper Norcross HealthUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 17 Jul 2027 (estimated)
- Study completion
- 17 Jul 2028 (estimated)
- First posted
- 9 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Participants are being approached to participate in this study because they are undergoing surgery for a skin cancer known as squamous cell carcinoma in situ (SCCIS) on the scalp. Standard surgical techniques may remove deeper structures that contain hair follicles, which can result in permanent hair loss. This study evaluates whether a modified surgical technique, known as partial thickness excision, can preserve hair growth and improve cosmetic outcomes. Participation involves minimal risk beyond the standard risks of Mohs surgery. If patients choose to participate, their surgery will be performed using this technique, and photographs will be taken over time to evaluate hair regrowth and healing.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Partial Thickness Excision | Experimental | Procedure: Partial Thickness ExcisionParticipants will receive excision of their squamous cell carcinoma in situ of the scalp via partial thickness excision (removal of epidermal and superficial dermal tissue) in an effort to preserve hair follicles and hair growth potential. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults ≥ 18 years old
- Histologically confirmed SCCIS
- Lesions located in the hair-bearing scalp
- Ability to provide informed consent
Key exclusion criteria (6 listed)
- Invasive, poorly differentiated, or high-risk SCC features (e.g., perineural invasion)
- Recurrent SCC at the same site
- Prior radiation therapy to the scalp
- Scarring alopecia or active inflammatory scalp disease at the treatment site
- Immunosuppression that, in the investigator's judgement, increases oncologic risk
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Partial Thickness ExcisionParticipants will receive excision of their squamous cell carcinoma in situ of the scalp via partial thickness excision (removal of epidermal and superficial dermal tissue) in an effort to preserve hair follicles and hair growth potential. | Procedure or surgery | Partial Thickness Excision |
Primary outcome
Hair Growth measured clinically by hair density percentage compared to baseline photo
Time frame: 3 and 6 months post-procedure.
To evaluate hair growth following partial thickness excision of SCCIS at 3 and 6 months post-procedure.
3 secondary outcomes
Clearance of SCCIS measured by Mohs surgeons' interpretation of margins on surgical slides.
Time frame: Immediately following the final Mohs stage during the index procedure
Patient Satisfaction measured via patient satisfaction questionnaire
Time frame: 3 and 6 months post-procedure
Complications
Time frame: 2 weeks post-procedure, 3 months post-procedure, and 6 months post-procedure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2026.
Related trials for Squamous Cell Carcinoma (Skin)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Active, not recruitingPhase 1
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Breast Cancer, Ovarian Cancer
RecruitingPhase 2
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
RecruitingPhase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Non Small Cell Lung Cancer, Triple Negative Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Partial Thickness Excision in people with Squamous Cell Carcinoma (Skin) and Squamous Cell Carcinoma in Situ, run by Cooper Norcross Health.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hair Growth measured clinically by hair density percentage compared to baseline photo (time frame: 3 and 6 months post-procedure.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.